By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
    Health
    Healthcare organizations are operating on slimmer profit margins than ever. One report in August showed that they are even lower than the beginning of the…
    Show More
    Top News
    HIPPA compliance
    How Medical Office Staff Can Make Your Practice HIPAA Compliant
    October 29, 2021
    Everything you need to know about hyaluronic acid treatment
    Everything you need to know about hyaluronic acid treatment
    February 10, 2022
    Which Mushroom Capsules Are Good for Your Health?
    May 5, 2022
    Latest News
    Why Custom Telemedicine Apps Outperform Off‑the‑Shelf Solutions
    July 20, 2025
    How Probate Planning Shapes the Future of Your Estate and Family Care
    July 17, 2025
    Beyond Nutrition: Everyday Foods That Support Whole-Body Health
    June 15, 2025
    The Wide-Ranging Benefits of Magnesium Supplements
    June 11, 2025
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
    Policy and Law
    Get the latest updates about Insurance policies and Laws in the Healthcare industry for different geographical locations.
    Show More
    Top News
    Image
    Healthcare Pricing Transparency Gains Momentum
    June 24, 2013
    non-clinical care factors in health outcomes
    Addressing Non-Clinical Care Factors in Health Outcomes
    November 15, 2013
    e interventions
    Healthcare Progress Depends On “E Interventions”
    July 10, 2014
    Latest News
    How IT and Marketing Teams Can Collaborate to Protect Patient Trust
    July 17, 2025
    How Health Choices and Legal Actions Intersect After an Injury
    July 17, 2025
    How communities and healthcare providers can address slip and fall injuries with legal awareness
    July 17, 2025
    Let Your Lawyer Handle the Work Before You Pay Medical Costs
    July 6, 2025
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Elmiron Controversy Highlights Need For Longterm Clinical Drug Testing
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Health care > Elmiron Controversy Highlights Need For Longterm Clinical Drug Testing
Health carePolicy & Law

Elmiron Controversy Highlights Need For Longterm Clinical Drug Testing

James Wilson
James Wilson
Share
8 Min Read
longterm clinical drug testing
Shutterstock Licensed Photo - By Sisacorn | stock photo ID: 412781575
SHARE

Elmiron has recently been the subject of a number of lawsuits brought about over claims that the drug causes vision problems and may lead to blindness. The drug (pentosan polysulfate sodium) is an oral medication prescribed for interstitial cystitis, which is thought to affect over 1 million Americans. Elmiron is produced in the US by Janssen Pharmaceuticals Inc, and those taking action claim that patients and doctors were not adequately informed of its risks. The controversy highlights the importance of clinical trials in the development of new drugs and the transparency of manufacturers when it comes to labeling products with potential risks.

The Elmiron lawsuits

It is not fully understood how Elmiron works, which in itself is perhaps a red flag. It is believed that it lines the mucosal layer of the bladder, preventing irritants reaching the bladder wall from the urine, but this was never confirmed before the drug was distributed. Elmiron was first approved in 1995, and Janssen Pharmaceuticals Inc has benefited from over $150 million in sales a year ever since, as it has become a common treatment for interstitial cystitis. Concern about the treatment is growing, however, with Elmiron lawyers reviewing an increasing number of cases involving severe side effects relating to vision. Patients who have experienced these severe side effects could now be entitled to compensation for Elmiron eye damage.

A common complaint amongst those who have experienced severe side effects has been maculopathy, which is notoriously difficult for patients to recognize. Symptoms include image distortion, difficulty adjusting to darkness, the appearance of a blindspot, and difficulty focusing on objects. The manufacturers did not originally warn of maculopathy as a potential side effect, but with the rising number of lawsuits against the company, Janssen Pharmaceuticals Inc have now changed warning labels to include a risk of ‘retinal pigmentary changes.’ 

More Read

How 12 Million are Putting “The Big C” Behind Them
Oxycontin and Heroin Addiction: Business Opportunities in the Push to Address the Problem
Emergency Nurses: An Overabundance of Violence
There is No Such Thing as an “Unbundled” Medical Bill
Can Online Degrees Launch Your Career in Top Medical Fields?

Warnings came too late

For many patients, this change in labeling has come too late. Some doctors may not have prescribed the medication for at-risk patients if the risk had been highlighted sooner. While trials were conducted for Elmiron, it is clear that more could have been done before the medication was distributed. One study, conducted since its release, found indisputable signs of drug toxicity in 22 patients in a sample of 91, and a number of case studies have shown a correlation between Elmiron and maculopathy.

Effective clinical trials should confirm that a drug works well and test for all potential side effects. Until comprehensive trials are undertaken, there is not enough evidence to show that a drug is safe or effective, and this puts patients at risk. Randomized clinical trials (RCTs) are generally regarded to be the best way of comparing treatments, but each step of the trial process is critical in order to ensure that only safe medication is approved. Many of the signs of maculopathy in Elmiron users were not seen until after three years of use, highlighting the need for long-term trials before medication is deemed safe.

Was Elmiron’s testing flawed?

Part of the difficulty in the Elmiron case is that the drug was subject to testing before it was approved by the FDA, and therefore, no rules were broken. Elmiron was tested in 2,627 patients over the course of two trials. By the time of the second trial, however, 52% of the subjects had either dropped out of the test or were no longer eligible. This highlights one flaw in the system: there must be measures in place to adequately test any medication even if the original cohort is no longer available for testing. 

In these original trials, it was seen that Elmiron relieved the pain affecting many patients within three months. For others, the pain was not reduced for six months. While pain relief did eventually reach these patients, it could be argued that a medication that takes six months to show effect should undergo further development. This is highlighted by the fact that another study published in the Journal of Urology found that pentosan polysulfate sodium taken orally provided little benefit to most interstitial cystitis patients.

Side effects seen in the original trials

In the original trials, most of the side effects associated with Elmiron were minor. However, out of the 2,627 strong sample, 33 patients did experience serious side effects. Six patients died, but it was concluded that this was caused by other health issues. 

The most common side effects were seen in 1-4% of the patients. One of these was alopecia, which began in the first four weeks of using the medication. Approximately 97% of participants lost hair in one place, which usually grew back once the drug was stopped. The other most common side effects were nausea, diarrhea, a rash, headaches, abdominal pain, stomach upset, dizziness and abnormal liver function. Some patients also experienced edema and weight gain. In a Phase 4 trial, 6.3% of patients given a daily dose of 300mg were affected by mild rectal hemorrhage. A further 15% taking a higher dose (900mg) had increased rectal bleeding. No vision problems were found in short-term use.

Adverse effects listed over time

By 2019, 2,460 adverse side effects were listed on the FDA Adverse Event Reporting System (FAERS) for Elmiron. 1,691 of these voluntary reports were serious, and 23 deaths were listed. However, while this does seem alarming, the FDA can’t confirm that these effects were related to the use of Elmiron, as this is not evidence from clinical testing; it is simply voluntary data. Nonetheless, this data is significant.

The clinical trials for Elmiron found side effects in patients over the course of the first year of drug use. However, for the majority of patients who have developed maculopathy, side effects were not seen until after at least three years of use. Clinical testing that does not study long-term side effects is arguably inefficient, and whether a drug should be approved so quickly after short-term trials is questionable.

It is clear that Elmiron has some benefits for interstitial cystitis patients. However, the study of potential side effects is as important as the study of a medication’s effectiveness, and the Elmiron controversy highlights the need for trials to take place over a number of years in order to identify all potential risks. Clinical trials are vital in the development of any new treatment, but it’s important that they are comprehensive enough to mitigate the risk to patients after long-term use.

TAGGED:clinical drug testinglongterm drug safety
Share This Article
Facebook Copy Link Print
Share
By James Wilson
James is a freelance writer and blogger. He loves to write on wellness, tech and E-Health.

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

botox certification
Help Improve People’s Skin Health Via Botox Certification
Skin Specialties
July 22, 2025
Telemedicine Apps
Why Custom Telemedicine Apps Outperform Off‑the‑Shelf Solutions
Health
July 20, 2025
Grounded Healing: A Natural Ally for Sustainable Healthcare Systems
How IT and Marketing Teams Can Collaborate to Protect Patient Trust
Global Healthcare Policy & Law
July 17, 2025
paramedics in surgical gloves and masks
How Health Choices and Legal Actions Intersect After an Injury
Health care
July 16, 2025

You Might also Like

Repeal and Do What Exactly?

March 31, 2012
healthcare technology
BusinesseHealthFinanceHealth ReformMobile HealthPolicy & LawTechnology

Technology May Make Capitation in Healthcare Work

July 31, 2013
Image
Public Health

There’s No Such Thing as Schizophrenia? Really?

May 19, 2013
Protecting Your Health: Why You Need an Attorney for Medical Malpractice
Health care

Protecting Your Health: Why You Need an Attorney for Medical Malpractice

February 25, 2024
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?